EUVIMEDEUVIMED entdecken
Open Access

Selective Elimination of Senescent Cancer Cells by Galacto-Modified PROTACs

Mengyang Chang, Feng Gao, Giri Gnawali, Hang Xu, Yue Dong, Xiang Meng, Wenpan Li, Zhiren Wang, Byrdie Lopez, Jennifer S Carew, Steffan T Nawrocki, Jianqin Lu und 2 weitere

Journal of Medicinal Chemistry · 09.05.2024 · 67 (9) · 7301-7311

DOI: 10.1021/acs.jmedchem.4c00152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 18.04.2024. Verfasst von Mengyang Chang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, United States. Hauptthemen laut MEDLINE: Cellular Senescence, Galactose, Prodrugs, Proteolysis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although the selective and effective clearance of senescent cancer cells can improve cancer treatment, their development is confronted by many challenges. As part of efforts designed to overcome these problems, prodrugs, whose design is based on senescence-associated β-galactosidase (SA-β-gal), have been developed to selectively eliminate senescent cells. However, chemotherapies relying on targeted molecular inhibitors as senolytic drugs can induce drug resistance. In the current investigation, we devised a new strategy for selective degradation of target proteins in senescent cancer cells that utilizes a prodrug composed of the SA-β-gal substrate galactose (galacto) and the proteolysis-targeting chimeras (PROTACs) as senolytic agents. Prodrugs Gal-ARV-771 and Gal-MS99 were found to display senolytic indexes higher than those of ARV-771 and MS99. Significantly, results of in vivo studies utilizing a human lung A549 xenograft mouse model demonstrated that concomitant treatment with etoposide and Gal-ARV-771 leads to a significant inhibition of tumor growth without eliciting significant toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cellular SenescenceGalactoseProdrugsProteolysisHumansAnimalsMiceAntineoplastic AgentsXenograft Model Antitumor Assaysbeta-GalactosidaseMice, NudeCell Line, TumorCell ProliferationA549 CellsEtoposideSenotherapeuticsProteolysis Targeting Chimera

Substanzen

GalactoseProdrugsAntineoplastic Agentsbeta-GalactosidaseEtoposideSenotherapeuticsProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, United States.
  • Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona 85721, United States.
  • Department of Medicine, University of Arizona, Tucson, Arizona 85721, United States.
  • University of Arizona Cancer Center, University of Arizona, Tucson, Arizona 85721, United States.

ORCID-Profile: Wei Wang

Förderung

  • NIEHS NIH HHS
  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Chang, M., Gao, F., Gnawali, G., Xu, H., Dong, Y., Meng, X., Li, W., Wang, Z., Lopez, B., Carew, J. S., Nawrocki, S. T., Lu, J., Zhang, Q. Y., & Wang, W. (2024). Selective Elimination of Senescent Cancer Cells by Galacto-Modified PROTACs. Journal of Medicinal Chemistry, 67(9), 7301-7311. https://doi.org/10.1021/acs.jmedchem.4c00152

Vancouver

Chang M, Gao F, Gnawali G, Xu H, Dong Y, Meng X, et al. Selective Elimination of Senescent Cancer Cells by Galacto-Modified PROTACs. Journal of Medicinal Chemistry. 2024;67(9):7301-7311. doi:10.1021/acs.jmedchem.4c00152

BibTeX
@article{Chang2024,
  author = {Chang, Mengyang and Gao, Feng and Gnawali, Giri and Xu, Hang and Dong, Yue and Meng, Xiang and Li, Wenpan and Wang, Zhiren and Lopez, Byrdie and Carew, Jennifer S and Nawrocki, Steffan T and Lu, Jianqin and Zhang, Qing-Yu and Wang, Wei},
  title = {Selective Elimination of Senescent Cancer Cells by Galacto-Modified PROTACs},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {9},
  pages = {7301--7311},
  doi = {10.1021/acs.jmedchem.4c00152}
}
Kostenlos starten →